EB-003

EB-003
Clinical data
Other namesEB003
Drug classNon-hallucinogenic serotonin receptor agonist; Psychoplastogen; Neurostabilogen

EB-003 is a non-hallucinogenic serotonin receptor agonist which is under development for the treatment of depressive disorders and anxiety disorders.[1][2][3][4][5] It is a tryptamine[1][5] and a derivative of the serotonergic psychedelic dimethyltryptamine (DMT).[3]

The drug acts as a non-selective agonist of serotonin receptors, including of the serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptors.[1][3][4][5] It is not a serotonin 5-HT2B receptor agonist.[5][6] EB-003 produces psychoplastogenic effects.[3][4][5] Due to targeting not only the serotonin 5-HT2A receptor but also the serotonin 5-HT1B receptor to influence neuroplasticity, EB-003 has been branded a new type of drug called a "neurostabilogen" by its developer.[3]

EB-003 is being developed by Enveric Biosciences.[1][2] As of February 2025, it is in the preclinical research stage of development.[1][2] A phase 1 clinical trial is being planned.[1] The drug's exact chemical structure does not yet seem to have been disclosed.[1][5] It has been patented, though the patent does not yet appear to have been published.[7]

See also

References

  1. ^ a b c d e f g "EB-003 - Enveric Biosciences". AdisInsight. 6 February 2025. Retrieved 16 February 2025.
  2. ^ a b c "Delving into the Latest Updates on EB-003(Enveric Biosciences) with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. ^ a b c d e Roberts, Madison (28 August 2025). "AbbVie's $1B Psychedelic Bet: Who's Next in the Neuroplastogen Gold Rush?". Microdose. Retrieved 22 October 2025.
  4. ^ a b c "Pipeline – Enveric Biosciences". Enveric Biosciences. Retrieved 16 February 2025.
  5. ^ a b c d e f "Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series". Financial Post. BusinessWire. 28 December 2023. Retrieved 16 February 2025.
  6. ^ "Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003". ENVB Stock News. 15 October 2024. Retrieved 16 February 2025.
  7. ^ "Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office". Yahoo Finance. 30 January 2025. Retrieved 16 February 2025.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.